Hymenoptera venom allergy significantly affects quality of life, and while allergen immunotherapy (AIT) is effective, predicting its success remains challenging due to a lack of biomarkers.
This study analyzed patient data from 1985 to 2022 at the University Hospital of Limoges to assess the role of IgE blocking activity as a potential predictor of AIT efficacy against Hymenoptera venom.
Results indicated that IgE blocking activity did not predict relapse after stopping AIT, but a correlation was found between this activity and IgG antibody levels, suggesting that further research is needed to explore the role of these antibodies in monitoring treatment outcomes.